Cargando…
Age-Related Maculopathy Susceptibility 2 and Complement Factor H Polymorphism and Intraocular Complement Activation in Neovascular Age-Related Macular Degeneration
PURPOSE: To investigate the association of risk alleles in complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) with complement activation products in the aqueous humor in eyes with neovascular age-related macular degeneration (nAMD) including polypoidal choroidal vasculopa...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559761/ https://www.ncbi.nlm.nih.gov/pubmed/36249678 http://dx.doi.org/10.1016/j.xops.2022.100167 |
_version_ | 1784807700823015424 |
---|---|
author | Kato, Yutaka Oguchi, Yasuharu Omori, Tomoko Kasai, Akihito Ogasawara, Masashi Sugano, Yukinori Itagaki, Kanako Ojima, Akira Ishida, Yumi Machida, Takeshi Sekine, Hideharu Sekiryu, Tetsuju |
author_facet | Kato, Yutaka Oguchi, Yasuharu Omori, Tomoko Kasai, Akihito Ogasawara, Masashi Sugano, Yukinori Itagaki, Kanako Ojima, Akira Ishida, Yumi Machida, Takeshi Sekine, Hideharu Sekiryu, Tetsuju |
author_sort | Kato, Yutaka |
collection | PubMed |
description | PURPOSE: To investigate the association of risk alleles in complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) with complement activation products in the aqueous humor in eyes with neovascular age-related macular degeneration (nAMD) including polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), and pachychoroid neovasculopathy (PNV). DESIGN: Prospective, comparative, observational study. PARTICIPANTS: Treatment-naïve patients with nAMD and cataract patients as controls. METHODS: The study included 236 eyes of 236 patients with nAMD and 49 control eyes of 49 patients. Aqueous humor samples were collected from 67 eyes with drusen-associated nAMD, 72 eyes with PCV, 26 eyes with RAP, and 71 eyes with PNV before intravitreal anti-VEGF injection and cataract surgery in the 49 control eyes. Clinical samples were measured for complement component 3a (C3a), C4a, and C5a using a bead-based immunoassay. Genotyping of the ARMS2 A69S (rs10490924), CFH I62V (rs800292), and CFH Y402H (rs1061170) was performed using TaqMan genotyping. MAIN OUTCOME MEASURES: The levels of complement activation products (C3a, C4a, and C5a) in the aqueous humor in each genotype of ARMS2 and CFH. RESULTS: The C3a level in the aqueous humor was significantly elevated (P = 0.006) in patients with nAMD and the ARMS2 A69S risk allele, whereas the levels of the complement activation products were not associated with CFH I62V and Y402H genotypes. Among the control eyes, no significant differences were seen in any complement activation products for all genetic polymorphisms. The levels of the complement activation products in the aqueous humor of eyes with the nAMD subtypes for each genetic polymorphism did not show significant differences. CONCLUSIONS: The C3a concentration in the aqueous humor was significantly higher in Japanese nAMD patients with the ARMS2 A69S risk allele, whereas it was not elevated in the patients with CFH I62V. Age-related maculopathy susceptibility 2 A69S polymorphism is strongly associated with local complement activation in nAMD patients. |
format | Online Article Text |
id | pubmed-9559761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95597612022-10-14 Age-Related Maculopathy Susceptibility 2 and Complement Factor H Polymorphism and Intraocular Complement Activation in Neovascular Age-Related Macular Degeneration Kato, Yutaka Oguchi, Yasuharu Omori, Tomoko Kasai, Akihito Ogasawara, Masashi Sugano, Yukinori Itagaki, Kanako Ojima, Akira Ishida, Yumi Machida, Takeshi Sekine, Hideharu Sekiryu, Tetsuju Ophthalmol Sci Original Article PURPOSE: To investigate the association of risk alleles in complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) with complement activation products in the aqueous humor in eyes with neovascular age-related macular degeneration (nAMD) including polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), and pachychoroid neovasculopathy (PNV). DESIGN: Prospective, comparative, observational study. PARTICIPANTS: Treatment-naïve patients with nAMD and cataract patients as controls. METHODS: The study included 236 eyes of 236 patients with nAMD and 49 control eyes of 49 patients. Aqueous humor samples were collected from 67 eyes with drusen-associated nAMD, 72 eyes with PCV, 26 eyes with RAP, and 71 eyes with PNV before intravitreal anti-VEGF injection and cataract surgery in the 49 control eyes. Clinical samples were measured for complement component 3a (C3a), C4a, and C5a using a bead-based immunoassay. Genotyping of the ARMS2 A69S (rs10490924), CFH I62V (rs800292), and CFH Y402H (rs1061170) was performed using TaqMan genotyping. MAIN OUTCOME MEASURES: The levels of complement activation products (C3a, C4a, and C5a) in the aqueous humor in each genotype of ARMS2 and CFH. RESULTS: The C3a level in the aqueous humor was significantly elevated (P = 0.006) in patients with nAMD and the ARMS2 A69S risk allele, whereas the levels of the complement activation products were not associated with CFH I62V and Y402H genotypes. Among the control eyes, no significant differences were seen in any complement activation products for all genetic polymorphisms. The levels of the complement activation products in the aqueous humor of eyes with the nAMD subtypes for each genetic polymorphism did not show significant differences. CONCLUSIONS: The C3a concentration in the aqueous humor was significantly higher in Japanese nAMD patients with the ARMS2 A69S risk allele, whereas it was not elevated in the patients with CFH I62V. Age-related maculopathy susceptibility 2 A69S polymorphism is strongly associated with local complement activation in nAMD patients. Elsevier 2022-04-30 /pmc/articles/PMC9559761/ /pubmed/36249678 http://dx.doi.org/10.1016/j.xops.2022.100167 Text en © 2022 by the American Academy of Ophthalmology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Kato, Yutaka Oguchi, Yasuharu Omori, Tomoko Kasai, Akihito Ogasawara, Masashi Sugano, Yukinori Itagaki, Kanako Ojima, Akira Ishida, Yumi Machida, Takeshi Sekine, Hideharu Sekiryu, Tetsuju Age-Related Maculopathy Susceptibility 2 and Complement Factor H Polymorphism and Intraocular Complement Activation in Neovascular Age-Related Macular Degeneration |
title | Age-Related Maculopathy Susceptibility 2 and Complement Factor H Polymorphism and Intraocular Complement Activation in Neovascular Age-Related Macular Degeneration |
title_full | Age-Related Maculopathy Susceptibility 2 and Complement Factor H Polymorphism and Intraocular Complement Activation in Neovascular Age-Related Macular Degeneration |
title_fullStr | Age-Related Maculopathy Susceptibility 2 and Complement Factor H Polymorphism and Intraocular Complement Activation in Neovascular Age-Related Macular Degeneration |
title_full_unstemmed | Age-Related Maculopathy Susceptibility 2 and Complement Factor H Polymorphism and Intraocular Complement Activation in Neovascular Age-Related Macular Degeneration |
title_short | Age-Related Maculopathy Susceptibility 2 and Complement Factor H Polymorphism and Intraocular Complement Activation in Neovascular Age-Related Macular Degeneration |
title_sort | age-related maculopathy susceptibility 2 and complement factor h polymorphism and intraocular complement activation in neovascular age-related macular degeneration |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559761/ https://www.ncbi.nlm.nih.gov/pubmed/36249678 http://dx.doi.org/10.1016/j.xops.2022.100167 |
work_keys_str_mv | AT katoyutaka agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT oguchiyasuharu agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT omoritomoko agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT kasaiakihito agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT ogasawaramasashi agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT suganoyukinori agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT itagakikanako agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT ojimaakira agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT ishidayumi agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT machidatakeshi agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT sekinehideharu agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration AT sekiryutetsuju agerelatedmaculopathysusceptibility2andcomplementfactorhpolymorphismandintraocularcomplementactivationinneovascularagerelatedmaculardegeneration |